Exosomes in Skin of Color: Dermatological Insights, Therapeutic Potential, and Clinical Realities in India.

Exosomes are nanosized extracellular vesicles that mediate intercellular communication by transferring proteins, lipids, and nucleic acids, and growing experimental evidence indicates their involvement in key cutaneous processes such as inflammation, melanogenesis, wound repair, angiogenesis, fibroblast activation, and hair follicle cycling. These biological properties have generated substantial interest in the use of exosome-based therapies in regenerative and aesthetic dermatology, although clinical adoption has often outpaced the strength of supporting evidence and regulatory oversight - particularly in India, where skin-of-color considerations, high disease burden, and rapid commercialization converge. This narrative review synthesizes current understanding of exosome biology, therapeutic potential, clinical evidence, and safety considerations in dermatology, with emphasis on pigmentary disorders, acne scarring, hair disorders, wound healing, and inflammatory dermatoses relevant to Indian practice. Preclinical studies suggest that mesenchymal stem cell- and skin-derived exosomes can modulate immune signaling, melanocyte function, angiogenesis, and extracellular matrix remodeling, while early clinical reports indicate possible benefits in pigmentation, scar modulation, hair loss, and tissue repair. However, available human data are largely derived from small, uncontrolled studies employing heterogeneous products and protocols, with limited representation of skin-of-color populations and insufficient long-term safety data. In the Indian context, gaps in product standardization, quality control, regulatory clarity, and informed consent further complicate clinical translation. While exosomes represent a promising frontier in dermatology, their use should presently be considered investigational and approached with caution, transparency, and robust ethical safeguards, until standardized manufacturing processes, population-specific trials, and comprehensive safety data become available.